Last updated on November 2019
A Phase 2 Multicenter Randomized Double-blind Placebo-controlled Study to Evaluate the Efficacy Safety and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Patients With Developmental and/or Epileptic Encephalopathies
Are you eligible to participate in this study?
You may be eligible for this study if you meet the following criteria:
-
Conditions: Epilepsy | Myoclonic Epilepsy | Lennox Gastaut Syndrome
-
Age: Between 2 - 17 Years
-
Gender: Male or Female
Inclusion Criteria:
- Male and female patients aged greater than or equal to (>=) 2 and less than or equal to (<=) 17 years
- Clinical diagnosis of Dravet Syndrome or LGS
- Weight of >=10 kilogram (kg) at the Screening visit
- Currently taking 1 to 4 anti-epileptic drugs (AED) at a stable dose
- Failed to become and remain seizure free with trials of at least 2 AEDs
Exclusion Criteria:
- Has been admitted to a medical facility and intubated for treatment of status epilepticus 2 or more times in the 3 months immediately prior to the screening visit
- Non-epileptic events that cannot be reliably distinguished from epileptic seizures
- Participation in a clinical study involving another study drug in the previous month
